Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine transdermal patch doses in idiopathic restless legs syndrome
2005-000428-18Phase 3Completed
- Sponsor
- Schwarz Pharma
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rotigotine in restless legs syndrome (RLS) (4 arms), sponsored by Schwarz Pharma. Primary endpoints: Efficacy over 6-month maintenance period and Safety and tolerability of rotigotine. Started Apr 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2005-000428-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000428-18.